Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International Inc    BAX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Baxter International Inc. : Technical Research on CareFusion and Baxter: Medical Equipment Companies on M&A Spree

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/25/2013 | 02:05pm CEST

LONDON, February 25, 2013 /PRNewswire/ --

Medical equipment sector is highly competitive and companies need to grow through constant innovations and mergers to remain relevant. The result is generally positive for the investors as Baxter International Inc. (NYSE: BAX) recently declared its quarterly dividend. The companies in this field are consolidating their positions as CareFusion Corporation (NYSE: CFN) is on the verge completing its acquisition of a Brazilian company. StockCall has posted free technical research reports on CareFusion and Baxter International and these can be accessed by signing up at

http://www.stockcall.com/analysis

Baxter International Inc. Announces Dividend

Baxter International Inc. announced its latest quarterly dividend at 45 cents per share. The company's dividend yield stands at 2.69 percent and the stock appreciated 17 percent in the past 52 weeks. The company recently completed the acquisition of OBI-1, a hemophilia compound from Inspiration Biopharmaceuticals. Inspiration is in the process to liquidate and hence, disposing off its assets. The acquisition of the compound will help Baxter International Inc. in consolidating its position in hemophilia market. Baxter International Inc. technical report can be accessed for free by signing up at

http://www.StockCall.com/BAX022513.pdf

Baxter International Inc. is generating good hedge fund buying interest as well. The company's stock is being held by Baker Ellis Asset Management LLC. It is also one of the biggest holdings of hedge fund Iridian Asset Management. Apart from this, Citadel Investment Group increased its stake in the company in the third quarter. Institutional buying is considered a good omen for the future performance of the stock.

The stock performed this year and is expected to keep up the momentum as it announced encouraging results for its fiscal fourth quarter. Its revenue for the quarter stood at $3.75 billion, surpassing consensus estimate of $3.71 billion. Its EPS matched analysts' expectations of $1.26 per share. This year it is likely to benefit from its acquisition of Swedish company, Gambro. The deal is expected to create synergies worth $300 million. Overall, the company has good prospects on the horizon.

CareFusion Corporation Touches New Highs

CareFusion recently created a new 52-week high and the stock rose 14.5 percent so far in this year. The company also reported good quarterly results with $909 million in revenue, up from $890 million in revenue it had reported for the second quarter of the last year. Its adjusted net income for the quarter stood at 54 cents per share. Thus, the company showed overall growth. Download the free report on CareFusion Corp. upon registration at

http://www.StockCall.com/CFN022513.pdf

CareFusion, however, got dropped by David Einhorn's Greenlight Capital Inc., which sold 4.59 million shares of the company in the third quarter. However, the stock grew 25 percent in the past 52 weeks and with its good results, the prospects for the stock are bright. Its stock is currently trading at Price/Earnings ratio of 18.91, in-line with industry standard, albeit a little on the higher side. Its high Price/Earnings ratio is, however, justified by the growth rate of the company.

CareFusion also undertook M&A exercise as it acquired Intermed Equipamento Medico Hospitalar late last year. The acquisition is expected to be finalized in the second quarter of this year and while it would be slightly dilutive in fiscal 2013, for fiscal 2014, the acquisition will have neutral impact. The long-term impact of the acquisition is expected to be positive.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAXTER INTERNATIONAL INC
04/24 BAXTER INTERNATIONAL INC : Pomerantz Law Firm Investigates Claims On Behalf of I..
04/20 BAXTER INTERNATIONAL : Introduces Comprehensive Guide for Building a Smart Infus..
04/19 BAXTER INTERNATIONAL : to Present at the UBS Global Healthcare Conference
04/19 Goldberg Law PC Announces an Investigation of Baxter International Inc.
04/19 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Baxter Internat..
04/18 BAXTER INTERNATIONAL : to Present at the Bank of America Merrill Lynch Healthcar..
04/18 BAXTER INTERNATIONAL : Shares of IV saline maker Baxter dip after employee gets ..
04/18 Lundin Law PC Announces an Investigation of Baxter International Inc. and Adv..
04/17 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baxter Inter..
04/17 BAXTER INTERNATIONAL : BAX) Negative on Subpoena
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
04/24DJWHAT'S NEWS : Business & Finance -- WSJ
04/24 Becton Dickinson to acquire Bard for $24 billion
04/23DJBECTON DICKINSON AND : to Acquire C.R. Bard for $24 Billion
04/19DJCardinal Swoops In, Strikes Deal -- WSJ
04/18DJCARDINAL HEALTH : $6.1 Billion Deal for Some Medtronic Operations Raises Debt Co..
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
04/24 Medical tech on the move after C.R. Bard sale
04/19 Pfizer subpoenaed in Fed's IV saline probe
04/14 Baxter faces DoJ criminal investigation into IV saline sales
04/10 Top 10 Healthcare Stocks For Dividend Growth And Income
04/06 Early-stage data support efficacy of Spark's hemophilia B candidate SPK-9001